

Press release

Jordbro, 30 April 2014

Change in the total number of shares and votes in Recipharm AB (publ) ("Recipharm")

In April 2014, the number of shares in Recipharm has increased by 10,443,038 shares of series B, corresponding to 10,443,038 votes, as a result of two new issues made in connection with Recipharm's IPO and subsequent listing on NASDAQ OMX Stockholm.

Furthermore, during the same period, 1,374,407 shares of series C have been issued in connection with the conversion of outstanding convertible bonds in Recipharm. These shares of series C have been converted into shares of series B. In total, 97.8 percent of the convertible bonds have been converted into shares.

As of 30 April 2014, the share capital in Recipharm amounts to SEK 18,594,437.50, divided into 12,685,716 shares of series A and 24,503,159 shares of series B. The total number of votes in Recipharm as of 30 April 2014 amounts to 151,360,319.

This information is published in accordance with Chapter 4, Section 9 of the Financial Instruments Trading Act (1991:980).

For further information please visit www.recipharm.com or contact:

Thomas Elderred, CEO, thomas.elderred@recipharm.com, telephone: +46 8 602 52 10

Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ OMX Stockholm. This information was submitted for publication on 30 April, 2014, at 12.00 pm CET.

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 1,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and pharmaceutical product development. Recipharm currently manufactures more than 200 different products to both Big Pharma and smaller research- and development companies. Recipharm's turnover is approximately SEK 2.1 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany and Spain and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com.